2.3.2 Gut microbiota and its metabolites modulate GLP-1 secretion Emerging evidence highlights a bidirectional regulatory interplay between the gut microbiota and GLP-1, whereby microbial composition and metabolites exert profound influences on GLP-1 synthesis, secretion, and signaling
In a February, 2024 interview with Bloomberg, Novo Nordisk CEO Lars Fruergaard Jrgensen whose company manufactures Ozempic and Wegovy even said that food companies had been calling him to voice fears over the impacts GLP-1 drugs have had on consumer spending
In diabetes, the drug is part of a tightly regulated metabolic control strategy
Vibrant Skin Brilliance is a lemon and peppermint-flavored supplement that improves both skin and liver health
Ipamorelin and sermorelin are not rapid-acting therapies
Although HIF-1 is primarily stabilized by the absence of oxygen, several mechanisms can also promote its stabilization in the presence of oxygen, including the regulation by mTORC1 (141, 142)